Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China

Partnership leverages Tenacia's expertise in central nervous system (CNS) drug development and commercialization to accelerate U.S. and global development of RAP-219 Tenacia obtains exclusive rights to develop and commercialize RAP-219 in Greater China across indications, including focal onset seizures and bipolar mania Rapport to receive upfront cash payment of $20 million, up to $308 million in potential development and commercial milestones and other payments, and mid-single-digit to mid-teens tiered royalties BOSTON and SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport”) a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, and Tenacia Biotechnology (Hong Kong) Co., Ltd (“Tenacia”), a commercial-stage biopharmaceutical company dedicated to developing innovative therapeutics for patients with underserved neurological disorders, today announced a collaboration granting Tenacia exclusive rights to develop and commercialize RAP-219 in Greater China, including in mainland China, Hong Kong, Macau and Taiwan. RAP-219 is a potential first-in-class TARPγ8-specific AMPA receptor negative allosteric modulator being developed as part of Rapport's growing neuroscience portfolio, including in focal onset seizures (FOS) and primary generalized tonic-clonic seizures, as well as in bipolar mania.